Hannah Uckelmann is Junior Group Leader at the Frankfurt Cancer Institute. Her research focuses on studying the epigenetic regulation of self-renewal programs during cancer development and the discovery of new therapeutics. She and her team are interested in NPM1c-driven leukemogenesis with focus on novel therapeutic therapies in NPM1 mutant AML.
[more]
